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Abstract
Rationale The nucleus accumbens (Acb) shell and caudate-
putamen nucleus (CPu) are respectively implicated in the
motivational and motor effects of dopamine, which are
mediated in part through dopamine D2-like receptors
(D2Rs) and modulated by activation of the cannabinoid-1
receptor (CB1R). The dopamine D2/D3 receptor agonist,
quinpirole elicits internalization of D2Rs in isolated cells;
however, dendritic and axonal targeting of D2Rs may be
highly influenced by circuit-dependent changes in vivo and
potentially influenced by endogenous CB1R activation.
Objective We sought to determine whether quinpirole alters
the surface/cytoplasmic partitioning of D2Rs in striatal
neurons in vivo.
Methods To address this question, we examined the
electron microscopic immunolabeling of D2 and CB1
receptors in the Acb shell and CPu of male mice at 1 h
following a single subcutaneous injection of quinpirole
(0.5 mg/kg) or saline, a time point when quinpirole reduced
locomotor activity.
Results Many neuronal profiles throughout the striatum of
both treatment groups expressed the D2R and/or CB1R. As
compared with saline, quinpirole-injected mice showed a
significant region-specific decrease in the plasmalemmal
and increase in the cytoplasmic density of D2R-immuno-
gold particles in postsynaptic dendrites without CB1R-
immunolabeling in the Acb shell. However, quinpirole
produced a significant increase in the plasmalemmal
density of D2R immunogold in CB1R negative axons in
both the Acb shell and CPu.
Conclusions Our results provide in vivo evidence for
agonist-induced D2R trafficking that is inversely related to
CB1R distribution in postsynaptic neurons of Acb shell and
in presynaptic axons in this region and in the CPu.
Keywords Marijuana.Motor inhibition.Reward.
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Introduction
Dopamine acts through D1 and D2-like receptors (D2Rs)
that are highly expressed in neurons located within both the
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(Acb) and in the dorsal striatum, caudate-putamen nucleus
(CPu; Durstewitz et al. 2000; Missale et al. 1998; Noble
2003; Yao et al. 2008). Of these striatal receptors, the D2Rs
are particularly important because of their involvement in
impulsivity (Besson et al. 2010; Lee et al. 2009) and in the
beneficial and adverse motor side effects produced by
classic antipsychotic drugs, all of which are D2R blockers
(Artigas 2010; Schlagenhauf et al. 2008; Soiza-Reilly and
Azcurra 2009).
The motor effects mediated through D2Rs may be
ascribed not only to signaling in striatal neurons, but also
to the presynaptic inhibition of the release of dopamine and
other neurotransmitters from axon terminals derived from
extrinsic neurons (Bamford et al. 2004; Delle Donne et al.
1997; Hersch et al. 1997; Wang et al. 2006). In the Acb
shell, D2Rs are present in mesolimbic dopaminergic and
prefrontal cortical glutamatergic terminals consistent with
their role in modulation of cortico-striatal transmission
involved in motivated behaviors (Del Arco and Mora 2009;
Sesack and Grace 2010). In contrast to the Acb shell, many
of the D2Rs in the dorsolateral CPu are located on
somatosensory cortical and nigrostriatal dopaminergic
axons, where their activation can profoundly affect the
learning of motor habits (Kienast and Heinz 2006;
Schlagenhauf et al. 2008). Thus, many of the diverse
behavioral effect ascribed to quinpirole and other D2R
agonistsaremediatedthroughregion-specificneuralnetworks
within the Acb shell and CPu. In each region, however,
activation of the D2R may largely modulate glutamatergic
and dopaminergic transmission (Ikemoto 2002; Lee et al.
2009; Van Hartesveldt et al. 1992).
An intricate, yet potentially indirect, relationship exists
between the dopamine and cannabinoid systems. Many
neurons in the dorsal striatum and Acb co-express
dopamine D2 and cannabinoid CB1 receptors, and systemic
administration of the dopamine D2/3R agonist LY171555
(quinpirole) occurs with a concurrent upregulation of
endocannabinoid (anandamide) signaling (Giuffrida et al.
1999; Swanson et al. 1997; van der Stelt and Di 2003;V a n
Hartesveldt 1997). Increased CB1R activation augments
quinpirole-induced changes in locomotor activity (Gorriti et
al. 2005) suggesting that activation of D2Rs may be
mediated by subsequent activation of the endocannabinoid
system (Martin et al. 2008). Moreover, co-activation of
these receptors, in vitro, produces changes in intracellular
signaling cascades due to heterodimerization of these two
receptor types (Kearn et al. 2005; Glass and Felder 1997).
As such, dopaminergic activation may differ depending
upon presence or absence of CB1 receptors. In vitro studies
of cultured cells and isolated neurons show that agonist-
activated D2Rs are rapidly internalized and either degraded
or recycled to the plasma membrane (Kim et al. 2008;
Namkung et al. 2009; Skinbjerg et al. 2010) (Xiao et al.
2009). In vivo, however, the D2R subcellular distribution
may be influenced not only by agonist activation in
individual cells, but also by the activation of these receptors
in other neurons within a functional neural network in
which D2R activation affects the release of endocannabi-
noids or other modulators (Meschler et al. 2000). As such,
we used electron microscopic immunolabeling to test the
hypothesis that quinpirole elicits a region-specific in vivo
change in the surface/synaptic availability of D2 receptors
in striatal neurons expressing the CB1R 1 h following a
single injection of 0.5 mg/kg quinpirole, a dose that
suppressed locomotor activity in mice.
Materials and methods
Animals The experimental procedures were carried out in
accordance with the National Institutes of Health Guide-
lines for the Care and Use of Laboratory Animals, and
approved by the Institutional Animal Care and Use
Committees at Weill Medical College of Cornell University
and the University of Washington. The locomotor activity
of 12 adult male C57BL/6J mice (20–25 g; Jackson
Laboratory, Bar Harbor, ME) was recorded in locomotor
chambers (Med Associates, St. Albans, VT). These cham-
bers consist of Plexiglass boxes with six infrared beam bars
(1–2 on each side) positioned so as to measure both
horizontal movement and rearing. The mice were habituat-
ed to the test chamber for 60 min 2 days prior to drug
injection (day 1—habituation). The following consecutive
day, baseline measures of locomotor activity were recorded
(day 2—baseline measures). On the third consecutive day,
animals received a subcutaneous injection of either quinpirole
(0.5 mg/kg; n=6) or saline (control animals; n=6) and were
immediately placed into the test chamber for 60 min, during
which time locomotor activity was monitored (day 3—
locomotor testing). Drug effects on locomotor activity were
measured as ambulatory time and distance traveled. The data
were evaluated using a repeated measure ANOVA. Immedi-
ately following the 60-min test period, the mice were deeply
anesthetized by intraperitoneal injection of sodium pentobar-
bital (150 mg/kg) and brain tissue was fixed by vascular
perfused with 30 ml of a solution containing 3.75% acrolein
and 2.0% paraformaldehyde in 100 mM phosphate buffer,
pH 7.4 (PB) followed by 150 ml of 2% paraformaldehyde in
PB.
The acrolein-infused brains were removed from the
cranium and post-fixed for 30 min in 2% paraformaldehyde
in PB. Coronal sections of 40 μm were cut through the Acb
and striatum (Franklin and Paxinos 1997) using a Leica
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aldehyde-fixed tissue sections were collected in 0.1 MPB
and then placed for 30 min in a solution of 1% sodium
borohydride in 0.1 MPB to remove excess active aldehydes.
Antisera The full C terminus of the rat CB1R( W a g e r - M i l l e r
et al. 2002) was used to generate a polyclonal antiserum in
guinea pig. This antiserum has been used previously for light
microscopic immunolabeling in mouse brain (Mulder et al.
2008) where the immunoreactivity has a distribution pattern
similar to that seen using an extensively characterized rabbit
antiserum also directed against the CB1R C terminus (Katona
et al. 1999;K a t o n ae ta l .2001). In the present study, we
further tested the specificity of the guinea pig CB1R
antiserum by comparison of the striatal labeling in wild-
type and CB1R( −/−)m i c e .
A dopamine D2R antipeptide antiserum was generated in
rabbit against amino acids 216–311 of the human D2R long
isoform (D2LR; Brana et al. 1997), which was cloned into
the pET30c plasmid (Novagen, Madison, WI, USA) and
confirmed by sequencing. The antiserum was affinity-
purified and shown to be specific by positive immunolabeling
in human embryonic kidney cells transiently transfected with
the pcDNA-FLAG-D2L plasmid (Kearn et al. 2005). In
Western blot analysis of rat brain homogenates, a single band
at 50 kDa was recognized by the D2LR antiserum, and pre-
adsorption with immobilized antigen eliminated the D2R
immunoreactive band as well as the immunolabeling seen in
sections through the rat forebrain (Pickel et al. 2006).
Electron microscopic dual labeling The dual-labeling pro-
tocol used for electron microscopy was modified from that
originally described by Chan et al. (1990). For this, the
prepared sections from the aldehyde-fixed tissue were
incubated overnight at room temperature in a mixture of
guinea pig anti-CB1R antiserum (1:1,000) and rabbit anti-
D2R antiserum (1:250) in a solution of Tris–saline containing
0.1% bovine serum albumin.
For immunoperoxidase labeling of the guinea pig CB1R
antiserum, sections previously incubated with both primary
antisera were washed and placed for 30 min in biotinylated
donkey anti-guinea pig immunoglobulin (IgG, 1:200;
Jackson ImmunoResearch Laboratories, West Grove, PA,
USA). These sections were then incubated for 30 min in
Vectastain ABC Elite kit (Vector Laboratories, Burlingame,
CA). The product was visualized by reaction in 3,3′-
diaminobenzadine (Sigma-Aldrich, St. Louis, MO) and
hydrogen peroxide. Subsequently, for immunogold labeling
of the rabbit D2R antiserum, the tissue was washed and
placed in a solution of Ultrasmall gold (Electron Micros-
copy Sciences, Hatfield, PA) conjugated to donkey anti-
rabbit IgG. The particles were visualized by using the
Silver IntensEM kit (GE Healthcare). The immunolabeled
sections of tissue were post-fixed in 2% osmium tetroxide
and embedded in plastic using conventional methods
(Leranth et al. 1989).
Electron microscopic data analysis The regions of the
ventromedial Acb shell and dorsolateral striatum in the atlas
of (Franklin and Paxinos 1997) were chosen for ultrastruc-
tural analysis. A Leica ultramicrotome (Leica Microsys-
tems, Wetzlar, Germany) was used to collect ultrathin
sections from the surface of two immunolabeled sections
from each of these regions in 12 mice (six receiving
quinpirole and six saline). These thin sections were
mounted on copper grids, counterstained using uranyl
acetate and lead citrate (Reynolds 1963), and examined
with a FEI Tecnai electron microscope (FEI, Hillsboro,
OR). The thin sections were initially examined at low (8–
9 K) magnification to identify the surface of the tissue, and
those regions showing immunolabeling of both CB1 and D2
receptors. These were then magnified and captured as
digital images. Thirty electron microscopic images at
×13,000 magnification were analyzed from the 24 blocks
of tissue (2 sections from each of the 12 mice).
Immunoperoxidase labeling was regarded as positive
when an electron dense precipitate, indicative of peroxidase
reaction product, was seen in selective profiles but absent in
adjacent profiles having otherwise similar ultrastructural
features. Immunogold-labeled structures were identified as
those containing one or more gold particles. This method
was validated in immunogold-labeled tissue by ascertaining
the absence of gold-silver deposits overlying myelin and
other structures, not known to express either D2 or CB1
receptors.
The labeling patterns in Acb shell and dorsal striatum
were quantitatively compared in thin sections taken from
the surface of vibratome sections from each region.
Electron microscopic images were obtained from a total
tissue area of 41,616 μm
2, representing 10,404 μm
2 in each
of four categories (CPu saline, CPu quinpirole, Acb saline,
and Acb quinpirole). The immunolabeled structures were
separated into categories of dendrites (dendritic shafts and
spines), axon terminals, small neuronal profiles (mainly
unmyelinated axons and spine necks), or glial processes
according to the nomenclature of Peters et al. (1991).
Labeled terminals were further defined with respect to the
type of synaptic specialization and immunolabeling in the
targeted neuron. Chi square, ANOVA, and paired t test
analysis were done using JMP software (SAS Institute,
Cary, NC). Figures were prepared from the acquired digital
images by initial adjustment of contrast and brightness
using Adobe Photoshop CS4 and Microsoft Office Excel
and PowerPoint 2007 software.
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Quinpirole suppressed locomotor activity throughout the
60 min interval following systemic injection (Fig. 1). One
hour after injection, quinpirole also produced significant
regional and compartment-specific changes in the subcellular
distribution of D2R-immunogold particles in somatodendritic
and axonal profiles of mouse striatum. The D2Rc o n t a i n i n g
profiles were largely without CB1Ri m m u n o r e a c t i v i t y ,a
CB1R-specific product seen by light microscopy in the
striatum of wild-type, but not CB1R (−/−)m i c e( F i g .2).
Quinpirole-induced decrease in locomotor activity Prior to
quinpirole administration, there were no differences in
baseline measures of locomotor activity, either in the
ambulatory time or distance traveled, in mice used for the
present study. However, after a single subcutaneous injection
of quinpirole (0.5 mg/kg), mice showed a significant decrease
in the amount of time they were active (F (1, 20)=22.17, p<
0.05) and in the distance they traveled (F(1, 20)=18.92, p<
0.05) as compared with saline controls. Further, a repeated
measures ANOVA showed that although all animals moved
less across the 1 h time period (ambulatory time: (F(59,
1,180)=1.85, p<0.05; distance traveled: (F (59, 1,180)=
1.77, p<0.05), there was no significant interaction between
time and drug treatment (ambulatory time: (F (177, 1,180)=
1.16, p>0.05); distance traveled: (F (177, 1,180)=1.19, p>
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Fig. 1 Line graphs showing
locomotor activity in mice
receiving a single subcutaneous
injection (0.5 mg/kg) of the D2/
D3 receptor agonist, quinpirole,
or saline. Both ambulatory time
(a) and distance traveled (b) are
significantly reduced in the
quinpirole treated (open circle)
compared with saline-injected
control (open squares) mice and
with baseline measures of either
treatment group (filled circles
and squares). The quinpirole-
induced reduction in activity is
apparent within the first 5 min
after injection and continues for
the duration of the 1-h test
period. Prior to quinpirole
administration (baseline
measures), mice show no
significant differences in loco-
motor activity (filled squares
indicate control mice, filled
circles indicate quinpirole mice).
Values are expressed as means
and standard errors; n=6 animals/
treatment group; *p<0.05
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in locomotor activity over time.
Somatodendriticdistributionandquinpirole-inducedtrafficking
of D2Rs In both the Acb shell and dorsal striatum, D2R
immunogold was discretely localized to the plasma mem-
brane or associated with cytoplasmic endomembranes in
somatodendritic profiles (Fig. 3). In somata, these endo-
membranes included smooth endoplasmic reticulum and
Golgi lamellae near the nuclear membrane (Fig. 3a, b).
Fig. 2 Light micrographs show-
ing immunoperoxidase labeling
for the guinea pig anti-CB1R
antiserum in a coronal section
through the dorsal striatum of a
C57/BL6J wild-type (A), but not
aC B 1R( −/−) mouse. c.c. corpus
callosum. Scale bar=100 μm
Fig. 3 Electron micrographs showing D2R immunogold particles
within the cytoplasm (small black arrows) and on the plasma
membrane (white block arrows) of somatodendritic profiles without
detectable CB1R immunoperoxidase labeling in the Acb shell (a) and
dorsal striatum (G-D). In a and b, the somata are contacted by axonal
profiles that are either unlabeled terminals (Ut-1–2), CB1R
immunoperoxidase-labeled terminals (CB1-t) or D2R containing axons
(D2-ax) or terminals (D2-te). In c, immunogold particles identifying
the D2R are seen in a transversely sectioned medium-diameter
dendrite (D2-de). This dendrite receives an inhibitory-type synapse
fromanaxonterminal(CB1R-t) showing faint CB1R-immunoperoxidase
labeling. In d,t h ec y t o p l a s m i cD 2R-immunogold particles are localized
to endomembranes (asterisk) in the transition zone between the plasma
membrane at an excitatory-type synapse and the outer membrane of a
mitochondrion (m). Unlabeled terminals (Ut-1 and Ut-2) are presynaptic
to the D2R-labeled dendrite. In e, cytoplasmic immunogold labeling
(arrows) for the D2R is seen in a small dendrite that also contains
CB1R-immunoperoxidase reaction product (D2-CB1-de) associated with
an endomembrane (asterisk) and the postsynaptic membrane speciali-
zation beneath a D2R-labeled axon terminal. Within this terminal, one
immunogold particle is in the cytoplasm (small black arrow) and the
second is in contact with the plasmalemma (block arrow). In bar graphs,
values are expressed as means and standard errors; n=6 animals/
treatment group; *p<0.05. In micrographs, scale bars=500 nm
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comprised more than half the total number of particles seen
in the Acb shell or CPu (Table 1). As compared with
somata, the D2R-immunogold particles in dendrites were
more frequently associated with the plasma membrane, but
retained their predominant cytoplasmic endomembrane
distribution (Fig. 3c, d). These endomembranes were often
located near mitochondria, being most prevalent between
the outer mitochondrial membrane and the postsynaptic
membrane specialization of excitatory synapses (Fig. 3d).
The immunoperoxidase labeling of the CB1R was also
localized to endomembranes in dendrites, inclusive of those
that contained D2R immunogold (Fig. 3e). The D2R and/or
CB1R-labeled dendrites received synaptic input from
unlabeled terminals and from terminals containing either
CB1Ro rD 2R, but rarely both receptors (Fig. 3). The
synaptic contacts onto these dually labeled dendrites were not
quantitatively examined, because of their small number. Only
12/3,715 of the D2R-labeled dendrites and 8/1,205 of the
D2R-labeled dendritic spines contained immunoperoxidase
reaction product for the CB1R.
Qualitative analysis of the D2R-labeling in mice receiving
quinpirole compared with saline suggested that quinpirole
administration induced internalization of D2Rs in dendrites,
the vast majority of which were without detectable CB1R
immunoreactivity in the Acb shell (Fig. 4a, b). Quantitative
analysis confirmed that in these dendrites quinpirole-induced
a significant region-specific decrease in the plasmalemmal
(F(1, 1,808)=8.28, p<0.05) and increase in the cytoplasmic
(F (1, 1,808)=7.37, p<0.05) density of D2R-immunogold
particles consistent with agonist-induced D2R internalization
(Fig. 4c). No similar changes were seen in the dorsal striatum
(Fig. 4d). Moreover, we saw no quantitative changes in the
distribution of D2R within dendritic spines in Acb shell or
striatum of mice with 1 h of quinpirole treatment (Data not
shown).
Axonal distribution and quinpirole-induced plasmalemmal
enhancement of D2Rs In both the Acb shell and dorsal
striatum, 33% of the D2R-immunogold particles were
located in axonal varicosities (Table 1). D2R-immunogold
particles were also located within small (<0.2 μm diameter)
profiles in these regions, many of which had the ultrastruc-
tural l features of were small axons. Isolated D2R-
immunogold particles were discretely located in the
cytoplasm overlying synaptic vesicles or in contact with
the plasmalemma in the axonal varicosities of each region.
These gold particles were also seen in many (n=991) small
(<0.2 μm diameter) profiles having the morphological
features of unmyelinated axons in the Acb shell and CPu
of mice receiving either saline or quinpirole. The majority
of the varicose axon terminals were without recognizable
synaptic junctions, but they also formed asymmetric or
more rarely symmetric synapses (Table 2), which are
typical of axon terminals containing glutamate and GABA,
respectively (Bellocchio et al. 1998; McDonald et al. 2002).
The D2R-labeled terminals forming asymmetric synapses
contacted mainly unlabeled (Fig. 5a)o rD 2R-labeled
(Fig. 5b) dendritic spines; whereas those forming
inhibitory-type synapses, principally contacted large den-
drites (Fig. 5c) or somata (Fig. 5d, e). The D2R-labeled
axonal varicosities were substantially more abundant than
those containing both D2R and CB1R immunoreactivity
(Table 2). However, the dually labeled terminals were
usually without recognizable synaptic membrane special-
izations within a single plane of section and were classified
as undefined (Fig. 5d, e; Table 2).
In the Acb shell, the plasmalemmal associated D2R-
immunogold particles in axon terminals appeared to be
slightly more prevalent in mice receiving quinpirole
compared with saline (Fig. 5a, b). Quantitative analysis
confirmed this impression and demonstrated a significantly
higher plasmalemmal density of D2R immunogold in axon
terminals without detectable CB1R immunoreactivity in the
Acb shell (F (1, 1186)=4.86. p<0.05; Fig. 6a). In the dorsal
striatum of mice receiving quinpirole, there was also a
significant (F (1, 1,173)=3.96, p<0.05; Fig. 6b) increase in
the plasmalemmal D2R immunogold in axon terminals,
although this increase was not as readily apparent from
qualitative observations. The quinpirole-induced plasma-
Table 1 Percentage of D2R-immunogold particles overlying dendritic and axonal profiles in the caudate nucleus and accumbens shell of mice
receiving either saline or quinpirole
All groups Caudate nucleus Accumbens shell
Saline Quinpirole Saline Quinpirole
Dendrites (%) 54 53 55 54 54
Dendritic spines (%) 13 13 15 10 11
Axonal varicosities (%) 33 34 30 36 35
Total
a 10,782 2,915 2,810 2,530 2,527
an=total number of D2R-immunogold particles in an area of 20,808 μm
2 tissue in the caudate nucleus and an equal area in the nucleus
accumbens shell of 12 mice that received saline or quinpirole
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particles was accompanied by a small, non-significant
increase in the cytoplasmic density of these particles in
the Acb shell (F (1, 1,186)=0.78, p>0.05). This increase in
cytoplasmic density may have contributed to the significant
increase in the total (plasmalemmal and cytoplasmic)
Fig. 4 Quinpirole-induced shift in D2R-immunogold particles from
the plasma membrane (block arrows) to the cytoplasm (small black
arrows) in dendritic profiles preferentially located in the Acb shell.
Electron micrographs showing the immunogold silver D2R labeling in
sections through the Acb shell of a mouse receiving saline (a)o r
quinpirole (QNP; b 1 h prior to sacrifice). In these micrographs,
CB1R-immunoperoxidase-labeled axon terminals (CB1-t, CB1-ax)
form asymmetric excitatory-type synapses with dendritic spines, some
of which show D2R immunogold (D2-sp) as do nearby D2R-
immunogold-labeled terminals (D2-t). c Bar graphs indicating that as
compared with saline-injected controls, mice receiving quinpirole
have a statistically significant (asterisk) reduction in plasmalemmal
(number of particles per unit length; PM/perim) and an increase in
cytoplasmic D2R-immunogold density (number of particles per unit
cytoplasmic area of the dendrite (CYT/area)). No between group
differences are seen in the total (plasmalemmal and cytoplasmic)
number of D2R-immunogold particles per unit area (TOTAL/area) in
dendrites of the Acb shell. d Bar graphs show no significant
differences between quinpirole and saline treatment groups in the
plasmalemmal, cytoplasmic, or total density of D2R-immunogold
particles in dendrites of the dorsal striatum. Scale bars=500 nm
Table 2 Percentage distribution of dendritic contacts formed by single (D2R) and dual (D2R+CB1R)-labeled axonal varicosities in the mouse
caudate nucleus and accumbens (Acb) shell
Caudate nucleus Nucleus accumbens shell
Contact D2R terminals D2R+C B 1R terminals D2R terminals D2R + CB1R terminals
Asymmetric (%) 40 9 36 17
Symmetric (%) 4 15 10 19
Undefined (%) 56 76 54 64
Total
a 1,173 132 1,186 110
an=number of labeled varicosities seen in an area of 20,808 μm
2 in the caudate nucleus and an equal area in the accumbens shell of 12 mice that
received either saline or quinpirole
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region when they expressed D2R alone (F (1, 1,186)=6.40,
p<0.05;Fig.6a) but not together with the CB1R( F (1, 110)=
1.6, p>0.05; Fig. 6c). Dual-labeled terminals in the dorsal
striatum (Fig. 6d)a l s of a i l e dt os h o wac h a n g ei nt h e
total (plasmalemmal and cytoplasmic) density of D2R
Fig. 5 Electron micrographs showing D2R-immunogold labeling in
axon terminals (D2-t) within the Acb shell of mice having 1 h
previously received quinpirole (QNP) or saline. Images in a and b
provide qualitative evidence for increased plasmalemmal (white block
arrows)D 2R-immunogold labeling in axon terminals (D2-t) forming
asymmetric, excitatory-type synapses with dendritic spines. These
terminals are without detectable CB1R-immunoperoxidase labeling, as
is the terminal in c which forms a symmetric synapses with and
unlabeled dendrite (U-de). In contrast, the inhibitory-type terminals
(D2/CB1-t) seen in d and e contain both D2R-immunogold and CB1R-
immunoperoxidase labeling with no apparent treatment-specific
differences in the plasmalemmal D2R distribution. The dually labeled
terminal forms a synapses with a D2R-labeled soma (D2-soma) in d
and an unlabeled soma (U-soma) in e. Small black arrows indicate
cytoplasmic and block arrows indicate plasmalemmal D2R-immuno-
gold particles. Microscopic scale bars=500 nm
Fig. 6 Bar graphs showing that D2R-immunogold particles in axon
terminals without CB1R labeling have a significantly greater plasma-
lemmal density, number/length axonal plasma membrane or, perimeter
(PM/perim) in the Acb shell (a) and striatum (b) of mice receiving
quinpirole (QNP) compared with saline. In the Acb shell of mice
receiving quinpirole, there is also a significant increase above the
salinecontrolsinthetotaldensity(cytoplasmic+ plasmalemmal) ofD2R-
immunogold particles in axon terminals. Neither the plasmalemmal,
cytoplasmic, nor total densities of D2R-immunogold particles in dually
labeled terminals in the Acb shell or dorsal striatum (c and d)
significantly differ between quinpirole and saline-injected mice. Values
are expressed as means and standard errors; n=6 animals/treatment
group; *p<0.05
108 Psychopharmacology (2012) 221:101–113immunogold in mice receiving quinpirole (F (1,132)=0.02,
p>0.05).
Discussion
Our results provide in vivo evidence for region-specific
trafficking of D2Rs in dendritic and axonal compartment
without detectable CB1R labeling in mouse striatum at 1 h
following systemic administration of quinpirole. The
preferential quinpirole-induced plasmalemmal to cytoplas-
mic redistribution of D2R-immunogold particles in den-
drites of the Acb shell suggests that postsynaptic neurons in
this region show agonist-induced D2R internalization that is
detectable at 1 h following drug administration. At this time
point, however, we observed an increase in the plasma-
lemmal density of D2R immunogold in axonal varicosities
in both the Acb shell and CPu of mice receiving quinpirole
compared with saline. This suggests that the agonist-
induced internalization of D2Rs seen in dendrites either
does not occur or is followed by a more rapid surface
replenishment in striatal axon terminals. The quinpirole-
induced changes in the pre- and/or postsynaptic surface
availability of D2Rs particularly in the Acb shell may result
in disinhibition of output neurons in the ventral pallidum
mediating, in part, the suppression of locomotor activity
(Hooks and Kalivas 1995; Nicola 2007; Sesack and Grace
2010) as is hypothetically diagramed in Fig. 7. These
findings demonstrate network-dependent changes in D2R
trafficking following activation, which would be difficult to
discern outside the context of an intact, functional system.
Trafficking of D2Rs in dendrites The observed decrease in
plasmalemmal and increase in cytoplasmic density of D2R
immunogold in postsynaptic dendrites of the Acb shell 1 h
following quinpirole administration suggests that the D2Rs
are being internalized to cytoplasmic compartments where
they are retained in a form recognizable by the D2R
antiserum. Cytoplasmic D2R immunogold in somata and
dendrites was often associated with endomembranes that
are involved in the dynamic transport of proteins in both
directions along dendritic microtubules(Gruenberg et al.
1989; Prekeris et al. 1998). The identity of these membranes
as portions of endomembrane systems associated with the
trafficking of G protein-coupled receptors is suggested by
their resemblance to early endosomes, where the receptors
are dephosphorylated and either retained or recycled back to
the cell surface (Seachrist and Ferguson 2003).
Few of the dendritic segments expressing D2Rs
contained CB1R labeling in mouse Acb shell or CPu, even
though these receptors are often co-expressed in these
regions of rat brain (Ong and Mackie 1999; Pickel et al.
Fig. 7 Simplified schematic diagram showing the hypothesized
quinpirole-induced D2R mobilization (dashed arrows) from the
plasma membrane to the cytoplasm in a postsynaptic dendrite. Block
arrows indicate extrinsic glutamatergic and dopaminergic inputs. An
intrinsic (cholinergic interneurons, Ach) somata is also shown to
provide input to a medium spiny neuron in the Acb shell. This spiny
neuron is shown as giving rise to local and extrinsic (ventral pallidum)
inhibitory-type terminals expressing both the D2R and CB1R. Within
this framework, locomotor inhibition would result from the heightened
D2R-mediated inhibition of the release of stimulatory transmitters
(glutamate and/or acetylcholine) onto a motor-activating spiny
projection neuron, whose activity is further suppressed by agonist-
induced activation of postsynaptic D2Rs
Psychopharmacology (2012) 221:101–113 1092006). The infrequent detection of CB1Ri m m u n o r e a c t i v i t y
in D2R-containing dendrites of mouse striatum may have
resulted in an underestimation of the dendritic co-expression
of these receptors in the present study. However, this would
not be expected to affect our comparison of the location of
D2Rs in quinpirole- versus saline-injected mice, since both
treatment groups would be subject to the same limitation.
CB1R expression in presynaptic terminals apposing D2R-
labeled dendrites In contrast with the low abundance of
CB1R immunoreactivity in D2R-containing dendrites, the
CB1R was prevalent in axon terminals providing synaptic
input to these dendrites. The respective location of D2 and
CB1 receptors in dendrites and their afferent terminals,
many of which form asymmetric excitatory-type synapses,
supports prior evidence that activation of postsynaptic D2Rs
contributes to the mobilization of endocannabinoids that
suppress glutamate release through activation of presynap-
tic CB1 receptors (Eilam and Szechtman 1989). More
excitatory-type terminals contain CB1 receptors in the Acb
shell compared with the core (Pickel et al. 2004), a region
that receives less extensive glutamatergic input from the
prefrontal cortex and shows both structural and functional
similarity to the CPu (Zahm 2000). Thus, our detection of
dendritic trafficking of the D2R receptor in the Acb shell,
but not the CPu, may reflect in part a more substantial D2R-
mediated change in endocannabinoid signaling affecting the
presynaptic release of glutamate from prefrontal cortical
inputs to the Acb shell (Robbe et al. 2002).
Increased presynaptic plasmalemmal density of D2Rs We
observed an increase in plasmalemmal density of the D2R
with (Acb shell) or without (dorsal striatum) a concomitant
increase in the cytoplasmic density of these receptors in
axon terminals at 60 min following quinpirole administra-
tion. Our observations support the in vitro evidence that
quinpirole elicits an accumulation of D2R/sGi2, a spliced
variant of the GTP-binding protein G(alpha i2), in neurites
and membranes (Tirotta et al. 2008). This effect may be
secondary to the activation and internalization of D2Rs,
which can occur within as little as 20 min following
quinpirole administration (Kita et al. 2007). Thus, at 1 h
following systemic administration of quinpirole, the
internalized D2R sm a yb ea l r e a d yr e t u r n e dt ot h e
plasmalemmal surface where newly recruited receptors
are also accumulated. The structural diversity of the D2R-
containing axonal profiles included among those showing
a quinpirole-induced enhancement of plasmalemmal D2Rs
suggests that they arise from extrinsic as well as local
striatal neurons.
The axon terminals showing quinpirole-induced up-
regulation of plasmalemmal D2Rs include the many
varicosities without clearly defined synaptic specializations,
a feature that is typical of dopaminergic inputs to both the
dorsal and ventral striatum (Nirenberg et al. 1997; Pickel et
al. 1997). Presynaptic D2 autoreceptors are prevalent
throughout the striatum, where low doses of quinpirole
are highly effective in producing calcium-dependent inhibition
of the spontaneous release of dopamine (Garcia-Sanz et al.
2001). Although endocannabinoids can modulate D2R-
mediated inhibition of dopamine release (O’Neill et al.
2009), there is to our knowledge no evidence that the CB1R
is present in dopaminergic terminals.
Of the D2R-labeled terminals forming synapses in the
Acb shell and CPu, the majority were characterized by
asymmetric, excitatory-type junctions typical of glutama-
tergic neurons (Charara et al. 1996; Torrealba and Mϋller
1999). A quinpirole-induced increase in the plasmalemmal
expression of D2Rs in these terminals within the Acb shell
is consistent with the fact that local injection of quinpirole
in this region decreases locomotor exploration, an effect
ascribed to D2R-dependent inhibition of glutamate release
(Kalivas and Duffy 1997; Mogenson and Wu 1991). A
quinpirole-induced increase in the presynaptic availability
of D2Rs in glutamatergic terminals might make these
terminals more susceptible to D2R-mediated inhibition of
glutamate release thus accounting for the functional
synergy between quinpirole and glutamate NMDA receptor
antagonists (Bortolato et al. 2005).
The relatively small number of D2R-labeled terminals
that formed symmetric inhibitory-type synapses in either
the Acb shell or CPu may reflect in part their inclusion in
the category of non-synaptic synapses because of the
difficulty in recognizing the thin pre- and postsynaptic
membrane specializations that are typical of GABAergic
neurons (Oertel and Mugnaini 1984; Pickel and Heras
1996; Smith et al. 1987). That the inhibitory-type terminals
containing D2R as well as the D2R and CB1R labeling may
have been underestimation in the mouse Acb shell and CPu
of the present study is suggested by our prior demonstration
that in these terminals are prevalent within these regions in
rat striatum (Pickel et al. 2006). However, the species
difference may also account for these observations in D2R
labeling in these terminals.
In contrast to axon terminals without CB1R immunolab-
eling, the subcellular distribution of D2Rs within dual-
labeled terminals did not significantly differ from saline-
injected controls. Systemic administration of quinpirole
produces an up-regulation of endocannabinoid signaling
(Giuffrida et al. 1999; Swanson et al. 1997; van der Stelt
and Di 2003; Van Hartesveldt 1997). Individually, D2 and
CB1 receptors are coupled to inhibitory G-proteins (Gi;
Bouaboula et al. 1999; Jarrahian et al. 2004). When co-
expressed, however, the dual activation of these receptors
results in the formation of D2/CB1 heterodimers linked to
stimulatory G-proteins (Gs; Glass and Felder, 1997; Kearn
110 Psychopharmacology (2012) 221:101–113et al. 2005; Pickel et al. 2006; Przybyla and Watts 2010).
Thus, the quinpirole-induced increase in plasmalemmal
D2Rs in axonal profiles may greatly enhance the D2R-
mediated inhibition of the release of neurotransmitters from
terminals that may also be subject to altered retrograde
endocannabinoid signaling (Patel et al. 2003). Further, the
formation of heterodimers when D2 and CB1 receptors are
co-expressed in inhibitory-type terminals may change
receptor dynamics providing a rationale for the lack of
significant plasmalemmal trafficking of D2Rs as seen in
profiles lacking CB1R labeling.
Conclusion
Our findings show that systemic quinpirole administration
produces region-specific and opposing changes in the
dendritic and axonal distributions of D2Rs which function
collectively to decrease striatal dopamine signaling. First,
quinpirole increased cytoplasmic D2R labeling in dendrites
within the Acb shell, whose neurons send extensive
inhibitory projections to the ventral pallidum, a critical
component in the neural network that normally has a
permissive role in locomotor activity (Churchill et al. 1992;
Kalivas et al. 1993; Murer et al. 2000). The quinpirole-
induced internalization of D2Rs in these cells, most likely,
contributed to the observed decrease in locomotor activity.
Second, there was increased plasmalemmal D2Rs in axonal
varicosities in the Acb shell and CPu. The greater
availability of presynaptic D2Rs on the plasma membrane
in these regions may significantly increase D2R-mediated
inhibition of the release of dopamine and other transmitters
that control motivational and sensorimotor activities
through the output circuitry of the basal ganglia (Balleine
et al. 2007; Belin et al. 2009). Finally, in contrast to D2R
single labeled profiles, axons containing CB1Rs did not
show significant plasmalemmal trafficking of D2Rs possi-
bly due to endocannabinoid mediated changes in receptor
dynamics. Together, our findings reveal quinpirole-induced
changes in the distribution of D2Rs that might not be
expected from agonist-induced internalization and traffick-
ing seen in vitro. This demonstrates the importance of
studying intact neural systems for understanding the
consequences of agonist activation on the availability of
functional surface receptors.
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